Diabetes Clinical Trial Tracker — Monitor Type 1, Type 2 & Metabolic Programs

Why monitoring diabetes trials is a full-time job

Diabetes is one of the largest therapeutic areas in clinical research. With GLP-1 receptor agonists reshaping the market, SGLT2 inhibitors expanding into heart failure and CKD, and cell therapy approaching commercial reality for Type 1 diabetes, the pipeline moves fast and the competitive stakes are high.

Professionals who need to track diabetes clinical trials include pharma BD teams evaluating licensing opportunities, biotech analysts covering the metabolic disease space, endocrinology CROs prospecting for trial management work, and patient advocacy organizations connecting T1D/T2D patients with clinical trials.

What TrialPulse monitors for diabetes

Configure your profile with condition keywords like "Type 2 Diabetes", "T1D", "GLP-1", "SGLT2", "insulin resistance", "diabetic nephropathy" — as broad or specific as your needs require. Filter by Phase 2/3 only, industry-sponsored trials, or all active studies.

Key diabetes trial signals to watch

• New GLP-1/GIP dual agonist Phase 2/3 programs competing with tirzepatide
• SGLT2 inhibitor combination trials in CKD, heart failure, and metabolic syndrome
• Cell therapy and islet transplant programs for Type 1 diabetes
• Oral insulin and novel delivery mechanism trials
• Non-alcoholic fatty liver disease (NAFLD/NASH) programs with diabetes endpoints
• Cardiovascular outcomes trials (CVOTs) — major milestone studies

How it compares to manual ClinicalTrials.gov searches

A search for "diabetes" on ClinicalTrials.gov returns thousands of results. Filtering by phase, sponsor type, and recruitment status, then exporting and comparing against yesterday's results to find what's new — that's a 45-minute task done manually. TrialPulse does it every morning and delivers only the delta: what's new and what changed.